首次挂牌无果，*ST赛隆拟降价10%继续“卖子”

Core Viewpoint - The company is planning to transfer 100% equity of its wholly-owned subsidiary, Hunan Sailong Biological Pharmaceutical Co., Ltd., through a public listing to optimize resource allocation and improve operational efficiency [2][5]. Group 1: Equity Transfer Details - The initial public listing for the transfer of Sailong Bio's 100% equity was held from January 23 to February 12, 2026, with a starting price set at RMB 86.95 million based on an assessment by Beijing Kunyuan Zhicheng Asset Appraisal Co., Ltd. [2] - Due to a lack of qualified buyers during the initial listing period, the company decided to reduce the listing price by 10% to RMB 78.255 million for the next round of public listing [2][3]. - If no qualified buyers are found after the next listing period, the company will apply for subsequent rounds of listing, with each round's price reduced by 10% from the previous [3]. Group 2: Financial Performance of Sailong Bio - Sailong Bio has been operating at a loss, reporting a loss of RMB 2.5186 million for the fiscal year 2024, which expanded to RMB 15.0288 million in the first three quarters of 2025 [4]. - Revenue for the first three quarters of 2025 was RMB 8.9229 million, while the total revenue for 2024 was RMB 10.9844 million [4]. - As of September 30, 2025, Sailong Bio's net assets were RMB 25.0493 million, down from RMB 40.077 million at the end of 2024 [4]. Group 3: Strategic Implications - The ongoing public listing of Sailong Bio's equity is aimed at optimizing the company's resource allocation, revitalizing assets, and enhancing operational efficiency, which aligns with the company's strategic development plan [5]. - The company emphasizes that the transaction will not harm the interests of shareholders, particularly minority shareholders, and the proceeds will be used for business development [5]. - The company retains the right to terminate the listing if no qualified buyers are found, and the final transaction price and counterparties will depend on the results of the public listing [3][5].